The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has directed Zydus ...

Heart failure is responsible not only for high morbidity and mortality, but also for significant out-of-pocket expenses for ...

Strong chronic therapy performance, BSV consolidation drive revenue growth in Q4; net profit declines 10 per cent ...

Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases ...

If the new data is added to the label of Jardiance (empagliflozin), the SGLT2 inhibitor would become the first in the class to be approved to treat all types of chronic heart failure as well as ...

Top of the agendas was chronic kidney disease (CKD), an area where Boehringer is already making an impact with blockbuster SGLT2 inhibitor Jardiance (empagliflozin). Jardiance was originally ...

Shares of Mankind Pharma dropped over 3 per cent after it posted a 10 per cent fall in consolidated net profit Q4 FY25 ...

The CANVAS Program integrated data from two trials involving a total of 10,142 participants with type 2 diabetes and high cardiovascular risk. Participants in each trial were randomly assigned to ...

A recent study published in the journal GeroScience has discovered that a diabetes drug called Empagliflozin (Empa) might ...

Introduction: Empagliflozin is a new sodium-glucose transporter protein 2 (SGLT2) inhibitor. In addition to its anti-hyperglycemic effect, recent studies suggested that it may improve cardiac outcomes ...